Q-omics provides the consensus-scored FAM86GP profile across patient tissues and cancer cell-line models. FAM86GP expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FAM86GP is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, FAM86GP RNA expression shows 17,254 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, and THYM as cancer lineages where FAM86GP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM86GP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM86GP survival associations across molecular data types. FAM86GP RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM86GP RNA expression–survival associations across cancer types. High FAM86GP expression shows unfavorable associations in KIRC, LGG, BLCA, UCS and LIHC, but favorable associations in BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FAM86GP RNA expression.
This table summarizes FAM86GP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for FAM86GP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM86GP shows lower tumor expression in KICH, UCEC and BRCA and higher tumor expression in KIRC, LIHC and COAD. The KIRC box plot shows higher FAM86GP RNA expression in tumor versus normal tissue (log2 FC = +0.864, t-test p < 0.001).
This table shows molecular features associated with FAM86GP in patient tissues and cancer cell lines. In patient samples, FAM86GP shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
